{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-208958","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.704645+00:00","generated_at":"2026-05-14T22:47:33.644407+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER","bullets":["Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.","Phase 1b dose optimization trial on track for 2026 completion; final cohorts 6 and 7 under enrollment with Cohort 6 nearing completion.","65% achieved complete remission vs 37% historical benchmark; 52% of remissions were MRD-negative.","No cytokine release syndrome reported; 6 patients proceeded to allogeneic stem cell transplant.","Phase 2 dose selection and regulatory interaction planned after dataset completion."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-208958","json":"https://secwatch.observer/filing/0001193125-26-208958.json","markdown":"https://secwatch.observer/filing/0001193125-26-208958.md","text":"https://secwatch.observer/filing/0001193125-26-208958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526208958/0001193125-26-208958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526208958/apvo-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-14T22:47:33.644407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}